A Phase 3 interventional study of Acalabrutinib (ACP-196) and Rituximab in Chronic Lymphocytic Leukemia, sponsored by Acerta Pharma BV. Active, not recruiting at 157 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 28 under way, 6 of them phase 3. acalabrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 6th largest by enrollment, is one of 2 that started in 2017, is one of 9 in phase 3, reaches primary completion later than 4 of the 27 other live ones, and was the 8th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →11 of the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Austria, Brazil and 6 more countries
Ages 18–130
Zulfa Omer · Sites in United States
Ages 18+
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
Seema Bhat · Sites in United States
Ages 18+
By country, each count listing its studies:
acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 26 · Phase 3 9 · Phase 4 1
First in 2014; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 310 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 61 across the 39 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Acerta Pharma BV, one of the names counted as AstraZeneca. Under that name alone:
Acerta Pharma BV is the lead sponsor of 41 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 3 (25%) have results posted.
42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca: 6 open now, 21 under way, 5 of them phase 3. Of 18 finished, 10 (56%) have results posted.
Among the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca, this one is the 7th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2017, is one of 7 in phase 3, reaches primary completion later than 5 of the 20 other live ones, and was the 17th registered.
AstraZeneca’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2005.
9 of the studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT05057494Phase 3AstraZenecaA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 2027-07-15 |
| NCT05971251University of Alabama at BirminghamAddition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia | 2026-12-31 |
| NCT06757647Seema BhatAcalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 2026-12-31 |
| NCT05943496OHSU Knight Cancer InstituteTafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | 2027-01-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among AstraZeneca’s 42 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of CLL that meets published diagnostic criteria (Hallek 2008):
Active disease meeting ≥ 1 of the following IWCLL 2008 criteria for requiring treatment:
i. Unintentional weight loss ≥ 10% within the previous 6 months before screening.
ii. Significant fatigue (ECOG performance score 2; inability to work or perform usual activities).
iii. Fevers higher than 100.5°F or 38.0°C for ≥ 2 weeks before screening without evidence of infection.
iv. Night sweats for > 1 month before screening without evidence of infection.
Meet the following laboratory parameters:
Exclusion Criteria:
History of prior except for the following:
Serologic status reflecting active or C infection.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Acalabrutinib (ACP-196) Monotherapy
Drug: Acalabrutinib (ACP-196)
Investigator's Choice of Rituximab Plus Idelalisib or Bendamustine
Drug: Rituximab · Drug: Idelalisib · Drug: Bendamustine
Acalabrutinib monotherapy
Rituximab in combination with idelalisib or bendamustine
Idelalisib in combination with rituximab
Bendamustine in combination with rituximab
Progression-free Survival (PFS) Per Independent Review Committee (IRC) Assessment
To evaluate the efficacy of acalabrutinib monotherapy (Arm A) compared with idelalisib/rituximab or bendamustine/rituximab (Arm B) based on Independent Review Committee (IRC) assessment of progression-free survival (PFS) per International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria (Hallek 2008) with incorporation of the clarification for treatment-related lymphocytosis (Cheson 2012) hereafter referred to as IWCLL 2008 criteria in subjects with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). As planned and reported in the interim clinical study report (dated 17 July 2019), because the study did cross the boundary at interim analysis. IRC assessments were discontinued after the interim analysis. All IRC-related efficacy analyses in this clinical study report were based on the interim analysis data cutoff date of 15 January 2019. All other efficacy analyses were based on the final analysis data cutoff date of 03 September 2021.
Time frame: IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up
Progression-free Survival (PFS) Per Investigator Assessment
PFS per investigator assessment based on the final analysis data cutoff date of 03 September 2021.
Time frame: From randomization date to date of disease progression or death due to any cause or data cutoff date on 03Sep2021, whichever came first, regardless of use of subsequent anticancer therapy, until 53 months of follow-up.
IRC-assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 15 January 2019 From Interim Analysis
IRC-assessed overall response rate (ORR) including complete response (CR), CR with incomplete blood count recovery (CRi) nodular PR (nPR), and Partial Response (PR)
Time frame: IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up
Investigator Assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 03 September 2021
IRC-assessed overall response rate (ORR) including complete response (CR), CR with incomplete blood count recovery (CRi) nodular PR (nPR), and Partial Response (PR)
Time frame: Investigator assessments were done from randomization date until date of death or date of exit from study or data cut off date on 03Sep2021, whichever came first, up to 53 months of follow-up.
Overall Survival (OS)
Overall Survival (OS) was based on data cutoff date of 03Sep2021
Time frame: From randomization date to date of death due to any cause, or date of study discontinuation, or date of data cutoff on 03Sep2021, whichever came first until 54 months of follow-up.
Duration of Response (DOR) Per Independent Review Committee (IRC) Assessment Based on 15 January 2019 Data Cutoff From Interim Analysis.
Duration of Response (DOR) is defined as from the first documentation of CR, CRi, PR, or nPR to the earlier of the first documentation of disease progression or death from any cause.
Time frame: IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up
Duration of Response (DOR) Per Investigator Assessment Based on 03 September 2021 Data Cutoff
Duration of Response (DOR) is defined as from the first documentation of CR, CRi, PR, or nPR to the earlier of the first documentation of disease progression or death from any cause.
Time frame: Investigator assessments were done from randomization date until date of death or study discontinuation or data cutoff date on 03Sep2021, whichever came first up to 53 months of follow-up.
Time to Next Treatment (TTNT) Based on 03 September 2021 Data Cutoff
Time to Next Treatment (TTNT) is defined as the time from date of randomization to date of institution of non-protocol-specified treatment for CLL (or first dose date of acalabrutinib for Arm B subjects crossing over to receive acalabrutinib) or death due to any cause, whichever comes first.
Time frame: From randomization date to start of non-protocol specified subsequent anticancer therapy for CLL or death due to any cause or study discontinuation or data cutoff date on 03Sep2021,, whichever came first up to 53 months of follow-up.
A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia. A total of 310 subjects met the eligibility criteria and were randomized to the acalabrutinib arm (N = 155) and IR/BR arm (N = 155). All but 3 subjects (1 randomized to acalabrutinib and 2 randomized to IR/BR) received study treatment.
| Milestone | Arm A- Acala 100 mg BID- Overall Study Period | Arm B: Investigator Choice (IR or BR)-Main Study Period | Arm B- Inv Choice of IR Crossed Over to Arm A- Acala. 100 mg BID | Arm B- Inv. Choice of BR Crossed Over to Arm A- Acala. 100 mg BID |
|---|---|---|---|---|
| Started | 155 | 155 | 0 | 0 |
| Arm b treatment= idelalisib plus rituximab | 0 | 119 | 0 | 0 |
| Arm b treatment = bendamustine plus rituximab | 0 | 36 | 0 | 0 |
| Completed | 0 | 1 | 0 | 0 |
| Completed | 99 | 26 | 0 | 0 |
| Completed | 99 | 27 | 0 | 0 |
| Not completed | 56 | 128 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 13 | 14 | 0 | 0 |
| Withdrew: Death | 41 | 33 | 0 | 0 |
| Withdrew: Arm b crossed over to arm a acala 100 mg monotherapy | 0 | 80 | 0 | 0 |
| Milestone | Arm A- Acala 100 mg BID- Overall Study Period | Arm B: Investigator Choice (IR or BR)-Main Study Period | Arm B- Inv Choice of IR Crossed Over to Arm A- Acala. 100 mg BID | Arm B- Inv. Choice of BR Crossed Over to Arm A- Acala. 100 mg BID |
|---|---|---|---|---|
| Started | 0 | 0 | 63 | 17 |
| Completed | 0 | 0 | 42 | 14 |
| Not completed | 0 | 0 | 21 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 1 |
| Withdrew: Death | 0 | 0 | 18 | 2 |
To evaluate the efficacy of acalabrutinib monotherapy (Arm A) compared with idelalisib/rituximab or bendamustine/rituximab (Arm B) based on Independent Review Committee (IRC) assessment of progression-free survival (PFS) per International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria (Hallek 2008) with incorporation of the clarification for treatment-related lymphocytosis (Cheson 2012) hereafter referred to as IWCLL 2008 criteria in subjects with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). As planned and reported in the interim clinical study report (dated 17 July 2019), because the study did cross the boundary at interim analysis. IRC assessments were discontinued after the interim analysis. All IRC-related efficacy analyses in this clinical study report were based on the interim analysis data cutoff date of 15 January 2019. All other efficacy analyses were based on the final analysis data cutoff date of 03 September 2021.
| Months | Arm A: Acalabrutinib Monotherapy | Arm B: Investigators Choice |
|---|---|---|
| Progression-free Survival (PFS) Per Independent Review Committee (IRC) Assessment | NA (NA to NA) | 16.5 (14.0 to 17.1) |
PFS per investigator assessment based on the final analysis data cutoff date of 03 September 2021.
| Months | Arm A: Acalabrutinib Monotherapy | Arm B: Investigator's Choice |
|---|---|---|
| Progression-free Survival (PFS) Per Investigator Assessment | NA (45.8 to NA) | 16.8 (14.1 to 22.5) |
IRC-assessed overall response rate (ORR) including complete response (CR), CR with incomplete blood count recovery (CRi) nodular PR (nPR), and Partial Response (PR)
| Participants | Arm A: Acalabrutinib Monotherapy | Arm B: Investigator's Choice |
|---|---|---|
| IRC-assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 15 January 2019 From Interim Analysis | 126 | 117 |
IRC-assessed overall response rate (ORR) including complete response (CR), CR with incomplete blood count recovery (CRi) nodular PR (nPR), and Partial Response (PR)
| Participants | Arm A: Acalabrutinib Monotherapy | Arm B: Investigator's Choice |
|---|---|---|
| Investigator Assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 03 September 2021 | 128 | 130 |
Overall Survival (OS) was based on data cutoff date of 03Sep2021
| Months | Arm A: Acalabrutinib Monotherapy | Arm B: Investigator's Choice |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
Duration of Response (DOR) is defined as from the first documentation of CR, CRi, PR, or nPR to the earlier of the first documentation of disease progression or death from any cause.
| Months | Arm A: Acalabrutinib Monotherapy | Arm B: Investigator's Choice |
|---|---|---|
| Duration of Response (DOR) Per Independent Review Committee (IRC) Assessment Based on 15 January 2019 Data Cutoff From Interim Analysis. | NA (NA to NA) | 13.6 (11.9 to NA) |
Duration of Response (DOR) is defined as from the first documentation of CR, CRi, PR, or nPR to the earlier of the first documentation of disease progression or death from any cause.
| Months | Arm A: Acalabrutinib Monotherapy | Arm B: Investigator's Choice |
|---|---|---|
| Duration of Response (DOR) Per Investigator Assessment Based on 03 September 2021 Data Cutoff | NA (41.5 to NA) | 18.3 (11.9 to 21.7) |
Time to Next Treatment (TTNT) is defined as the time from date of randomization to date of institution of non-protocol-specified treatment for CLL (or first dose date of acalabrutinib for Arm B subjects crossing over to receive acalabrutinib) or death due to any cause, whichever comes first.
| Months | Arm A: Acalabrutinib Monotherapy | Arm B: Investigator's Choice |
|---|---|---|
| Time to Next Treatment (TTNT) Based on 03 September 2021 Data Cutoff | NA (46.9 to NA) | 22.5 (17.5 to 25.9) |
Collected over All adverse events were reported from randomization date until 30 days after the last dose of study drug or the start of new anticancer therapy (whichever comes first) up to 54 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A- Acala. 100 mg BID | 41/155 (26.5%) | 70/154 (45.5%) | 149/154 (96.8%) |
| Arm B: Investigator Choice (IR or BR)-Main Study Period | 33/155 (21.3%) | 86/153 (56.2%) | 145/153 (94.8%) |
| Arm B Cross Over | 20/80 (25%) | 31/80 (38.8%) | 73/80 (91.3%) |
| Event | Arm A- Acala. 100 mg BID | Arm B: Investigator Choice (IR or BR)-Main Study Period | Arm B Cross Over |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2/154 | 19/153 | 1/80 |
| PneumoniaInfections and infestations | 14/154 | 13/153 | 7/80 |
| PyrexiaGeneral disorders | 5/154 | 9/153 | 1/80 |
| AnaemiaBlood and lymphatic system disorders | 2/154 | 5/153 | 4/80 |
| Covid-19 pneumoniaInfections and infestations | 6/154 | 1/153 | 0/80 |
| Pneumonia pneumococcalInfections and infestations | 0/154 | 4/153 | 0/80 |
| EnterocolitisGastrointestinal disorders | 1/154 | 4/153 | 0/80 |
| Covid-19Infections and infestations | 3/154 | 1/153 | 2/80 |
| Septic shockInfections and infestations | 0/154 | 1/153 | 2/80 |
| Acute kidney injuryRenal and urinary disorders | 0/154 | 1/153 | 2/80 |
| Event | Arm A- Acala. 100 mg BID | Arm B: Investigator Choice (IR or BR)-Main Study Period | Arm B Cross Over |
|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 37/154 | 67/153 | 16/80 |
| DiarrhoeaGastrointestinal disorders | 32/154 | 64/153 | 10/80 |
| HeadacheNervous system disorders | 36/154 | 7/153 | 12/80 |
| Upper respiratory tract infectionInfections and infestations | 31/154 | 24/153 | 5/80 |
| AnaemiaBlood and lymphatic system disorders | 27/154 | 17/153 | 16/80 |
| PneumoniaInfections and infestations | 30/154 | 19/153 | 9/80 |
| PyrexiaGeneral disorders | 25/154 | 29/153 | 10/80 |
| CoughRespiratory, thoracic and mediastinal disorders | 27/154 | 20/153 | 8/80 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 20/154 | 8/153 | 14/80 |
| NauseaGastrointestinal disorders | 13/154 | 24/153 | 5/80 |
Analysis was performed on Intent-to-Treat (ITT) population, which included all randomized participants grouped according to assigned treatment.
| Age, Customized(Participants) | Arm A- Acala. 100 mg BID | Arm B: Investigator Choice (IR or BR)-Main Study Period | Total |
|---|---|---|---|
| Age < 65 Years | 58 | 57 | 115 |
| Age >=65 years | 97 | 98 | 195 |
| Sex: Female, Male(Participants) | Arm A- Acala. 100 mg BID | Arm B: Investigator Choice (IR or BR)-Main Study Period | Total |
|---|---|---|---|
| Female | 47 | 55 | 102 |
| Male | 108 | 100 | 208 |
| Ethnicity (NIH/OMB)(Participants) | Arm A- Acala. 100 mg BID | Arm B: Investigator Choice (IR or BR)-Main Study Period | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 6 | 8 |
| Not Hispanic or Latino | 147 | 129 | 276 |
| Unknown or Not Reported | 6 | 20 | 26 |
| Race (NIH/OMB)(Participants) | Arm A- Acala. 100 mg BID | Arm B: Investigator Choice (IR or BR)-Main Study Period | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 7 | 7 | 14 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 0 | 0 | 0 |
| White | 145 | 141 | 286 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 6 | 9 |
| Region of Enrollment(Participants) | Arm A- Acala. 100 mg BID | Arm B: Investigator Choice (IR or BR)-Main Study Period | Total |
|---|---|---|---|
| North America | 8 | 9 | 17 |
| Australia | 6 | 6 | 12 |
| New Zealand | 3 | 1 | 4 |
| Europe | 131 | 132 | 263 |
| Taiwan, Province Of China | 1 | 0 | 1 |
| Hong Kong | 0 | 1 | 1 |
| Korea, Republic Of | 3 | 4 | 7 |
| Singapore | 3 | 2 | 5 |
Showing the first 100 of 157 sites across 25 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Feb 2017 to primary completion in Sep 2021, 55 months.
Results were first posted in Jun 2023, 1 year 9 months after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 55 months is close to that.
Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acalabrutinib
Leukemia, Lymphocytic, Chronic, B-Cell →